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Essentials
• Patients at high-risk of occult cancer may benefit from extensive screening.
• We validated the RIETE cancer score in the MVTEP study.
• One in three patients were classified as high-risk, 10% of whom had cancer diagnosed.
• The RIETE score identifies a subgroup at high risk for cancer. The RIETE score seems to be able to identify a subgroup at high risk for cancer (10%) in our specific dataset of patients with unprovoked venous thromboembolism.
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Introduction
The association between venous thromboembolism (VTE) and occult cancer has been recognized since the publication by Trousseau [1] . Epidemiologic studies have suggested that the rate of occult cancer may reach 10% at 1 year after symptomatic VTE [2] , mainly in patients with unprovoked VTE [3] . Several studies have evaluated various strategies for occult cancer screening [4] . The two most recent trials failed to demonstrate the superiority of extensive screening (enhanced computed tomography [CT] in the SOME [5] trial; [¹⁸F]fluorodeoxyglucose-positron emission tomography [FDG-PET] in the MVTEP [6] trial) in patients with unprovoked VTE. The most likely explanation put forward to explain these negative findings was the lower than expected rate of occult cancer (~5%), despite the inclusion of patients with unprovoked VTE. Hence, current research is focused on the individualization of patients at higher risk for occult cancer. Recently, the investigators from the RIETE registry provided a score comprising seven simple items (male gender, age > 70 years, chronic lung disease, anemia, elevated platelet count, prior VTE, and recent surgery) [7] . This score seems to be able to select one-third of the population with a risk of occult cancer of > 10%. This score has been derived and validated in the patients included in the RIETE registry, but remains to be externally validated in a different dataset of patients. In the MVTEP study [6] , every included patient had acute symptomatic VTE, and was followed to assess the frequency of occult cancer.
Our aim was to evaluate the accuracy of the RIETE score among patients included in the MVTEP study.
Materials and methods
Patients
The methods of the MVTEP study have been published recently [6] . Briefly, all patients had an acute, unprovoked (not provoked by a major inherited or acquired risk factor), symptomatic VTE (deep venous thrombosis and/or pulmonary embolism). Patients were randomized to a limited screening strategy (physical examination, usual laboratory tests, and basic radiographs) or a screening strategy consisting of the limited strategy plus an FDG-PET/CT scan. Cancer diagnoses after completion of the initial screening strategy were collected during the 24-month follow-up.
Outcomes
Patients were classified according the presence of items proposed by the RIETE cancer score. Because of the MVTEP inclusion criteria, no patients had postoperative VTE. Moreover, chronic lung disease was not captured in the study case report form. Thus, for the purpose of this analysis, chronic lung disease was replaced by exposure to tobacco, the main risk factor for chronic lung disease. The primary outcome for this analysis was the diagnosis of cancer at any time during the 24 months following inclusion.
Study analysis
We conducted univariate analyses of the association between each of the variables in the RIETE score and cancer diagnosis, by the use of the v 2 test or the Fisher exact test when appropriate. The odds ratio (OR) for these associations was estimated, along with its 95% confidence interval (CI). We then retrospectively computed the score for all included patients. We performed a receiver operating characteristic (ROC) curve analysis, and estimated the area under the ROC curve and its 95% CI. Finally, patients were classified into two risk groups according to the threshold proposed in the derivation study. The rate of cancer diagnosis in each group was determined, and the OR of the association between the risk group and the rate of cancer was estimated. All analyses were performed with SPSS 24.0 (IBM, Chicago, IL, USA).
Results and discussion
Population study
Among the 399 patients included in the MVTEP study, five withdrew their consent. Two more patients were found to be ineligible because of the lack of confirmed VTE. Hence, 392 patients of the MVTEP study were included in the analysis.
The median age was 63 years (interquartile range [IQR] 49-76). Patients presented with pulmonary embolism in most cases (82%). Current tobacco use was noted in 17% of the patients, alcohol consumption in 9%, and asbestos exposure in 7%. A personal history and a family history of cancer were found in 5.6% and 32.6% of the patients, respectively. At the end of the 2-year follow-up, cancer was diagnosed in 25 (6.4%) patients (five prostate cancer, four hematologic cancer, three lung cancer, and three colon cancer for the most frequent; 13 at an early stage). An exhaustive description of these 25 patients can be found in the report of the main analysis from the MVTEP study [6] .
Frequency of risk factors
Among the 392 patients, 206 (53%) were male, 137 (35%) were aged > 70 years, 171 (44%) were current or former tobacco users, 39 (10%) had elevated platelet counts (missing values, n = 6), 76 (19%) had anemia (missing values, n = 4), and 116 (30%) had a history of VTE. The corresponding rates of each item according to cancer diagnosis are shown in Table 1 .
Occult cancer diagnosis according to the RIETE cancer score
The score was calculated for 386 patients (missing values for six patients from the original dataset), and ranged from À 1 to + 7, with a median of 2.0 (IQR 1-3) . The area under the ROC curve was 0.63 (95% CI 0.51-0.74). A total of 136 patients (35.3%) were classified as high risk by the score. Cancer was diagnosed in 16 (11.8%) of the 136 patients with a high-risk RIETE cancer score, and in nine (3.6%) of the 250 patients with a low-risk RIETE cancer score (Table 2) : OR 3.6 (95% CI 1.53-8.32).
Our study provides external validation of the RIETE score. Among patients with unprovoked VTE, the score is able to discriminate low-risk and high-risk patients. The 3% risk of cancer in the low-risk group appears to be low enough to reassure physicians and patients. Patients classified as being at high risk should be the targets of future studies on cancer screening strategies. If an accurate screening test or strategy is available, the number needed to be tested appears to be low enough for such a test or strategy to prove cost-effective. It is of note that, in our study, the c-statistic showed only modest discriminant ability of the score.
Our study has some limitations. First, we used as an outcome any cancer diagnosed after inclusion, including during the initial screening, whereas the RIETE score assesses the risk of occult cancer diagnosed beyond the first 30 days after VTE. However, in our study, only 10 patients had cancer diagnosed after a negative initial screening, limiting the power to detect any difference. Moreover, our study sample comprises two arms with very different cancer incidence during follow-up: only one patient was diagnosed with cancer following a negative PET/CT-based strategy, versus nine in the limited screening strategy arm. Finally, the assumption is that cancers diagnosed during the months following a VTE are already existing but occult malignancies. Therefore, we believe that predictors should not be too different for cancers diagnosed either at initial screening or during the following months. Second, we replaced the item 'chronic lung disease' with the item 'tobacco use'. The most frequent chronic lung disease is chronic obstructive lung disease, which is caused by tobacco exposure in almost all cases. We did not include the item 'postoperative VTE' in our analysis. It is of note that the frequency of occult cancer is extremely low in patients with VTE provoked by surgery [4] . This may explain why 'postoperative VTE' was negatively linked to occult cancer in the RIETE score. The question of searching for occult cancer does not seem to be relevant in patients with VTE provoked by surgery. Therefore, we think that removing this item is appropriate.
In conclusion, we confirm the ability of the RIETE cancer score to identify a subgroup of patients corresponding to one-third of the population study, with a risk of occult cancer of > 10% at 2 years. This rate seems to justify a new study evaluating extended screening strategies.
